We are advised by Merck Serono that journalists and other readers should disregard the news release "Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer" NYSE:SRA, issued today due to premature release. This release will be reissued at a later date.
Contact: Dr. Raphaela Farrenkopf, Phone +49-6151-72-2274
Please donate so science experts can write
for the public.
At Science 2.0, scientists are the journalists,
with no political bias or editorial control. We
can't do it alone so please make a difference.
We are a nonprofit science journalism
group operating under Section 501(c)(3)
of the Internal Revenue Code that's
educated over 300 million people.
You can help with a tax-deductible
donation today and 100 percent of your
gift will go toward our programs,
no salaries or offices.
Comments